People · Operator
Named in public records as an officer, director or promoter · active 2015–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Centrexion Therapeutics Corp | — | Biotechnology | Series C | $202.0M | $35.3M | 2017 |
| Mersana Therapeutics Inc | — | Biotechnology | Series B | $93.7M | $1.3B | 2015 |
SARA J. NAYEEM at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside SARA J. NAYEEM on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac Blech | 1 | 14 |
| Arnold Oronsky | 1 | 10 |
| David Mott | 1 | 9 |
| Thomas Beck | 1 | 7 |
| Elaine Jones | 1 | 6 |
| Sol Barer | 1 | 6 |
| Arnold L. Oronsky | 1 | 6 |
| Sol J. Barer | 1 | 6 |
| MICHAEL J. WARD | 1 | 5 |
| Sara Nayeem | 1 | 4 |
| C. Boyd Clarke | 1 | 4 |
| Isaac J. Blech | 1 | 3 |
| Sara G. Nayeem | 1 | 2 |
| PETER PARK | 1 | 2 |
| David G. Mott | 1 | 2 |
| Jeffrey B. Kindler | 1 | 2 |
| ELAINE J. JONES | 1 | 2 |
| Peter G. Park | 1 | 1 |
| Nicholas G. Bacopoulos | 1 | 1 |
| Burkhard B. Blank | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.